Finance Watch: Eleven Companies Reveal $1.45bn In $100m-Plus VC Deals
Venture Capital Boom Includes New Funds; OrbiMed Raises $3.5bn
Executive Summary
Private Company Edition: Clover’s $230m financing was the largest of recent mega-rounds. Century Therapeutics ($160m), Vividion ($135m) and eGenesis ($125m) also raised big rounds and investors Foresite Capital ($969m), Sofinnova Partners ($540m) and OMX Ventures ($150m) raised new VC funds.
You may also be interested in...
Finance Watch: FogPharma’s Platform Against Unreachable Targets Attracts $145m Series E
Private Company Edition: FogPharma raised $145m for its clinical-stage drug and earlier programs after bringing on former Johnson & Johnson R&D head Mathai Mammen as CEO last year. Also, BlossomHill closed a $100m series B round and Kenai emerged with $82m in series A cash.
Novo Nordisk Calls On Two Flagship Firms For Early Science In Metabolic Health
Derived from a 2022 collaboration between the two, Novo Nordisk will partner with Flagship-backed Omega in obesity and Cellarity in NASH. Both programs are in very early stages at present.
Finance Watch: Mega-Round Mania As RNA Therapeutics, Gene Editing Attract VC Cash
Private Company Edition: Two companies raised multiple hundreds of millions of dollars each helping to keep the number of $100m-plus venture capital mega-rounds on the rise in May. Also, Ascend raised $132.5m to make gene and cell therapies, and Nido emerged with $109m for neurological diseases.